Schedule information is subject to change. Last updated 3 March 2025.
Thursday, 5 June
Hosted at the University of Chicago Gleacher Center and in collaboration with the Society for Immunotherapy of Cancer (SITC)
| Time |
Session |
| 7:00 a.m. |
Registration Open & Breakfast Served |
| 8:00 a.m. - 12:00 p.m. |
Session 1: Advances in Cancer Immunotherapy: A Focus on Interventional Oncology, presented by SITC
Additional details to be announced soon
|
| 12:00 - 1:00 p.m. |
Lunch |
| 1:00 - 2:15 p.m. |
Session 2: Interventional Oncology: Transarterial Therapies Primer
- Chemoembolization: Current State of the Science
- Radioembolization: Radiation Basics of Y90
- Resin Microsphere Dosimetry
- Glass Microsphere Dosimetry
- Discussion
|
| 2:15 - 2:30 p.m. |
Break |
| 2:30 - 4:30 p.m. |
Session 3: Biomarkers
- Keynote: How Does Immunotherapy Fit with Locoregional Therapies
- Immunological Effects of Local Therapies in the Tumor Microenvironment
- Unraveling Mechanisms of Resistance to Immunotherapy in HCC
- Imaging Biomarkers of Response to Immuotherapy in Liver Cancer
- Minimal Residual Disease after TACE
- Discussion
|
| 4:30 - 4:45 p.m. |
Break |
| 4:45 - 5:45 p.m. |
Session 4: Sequencing
- Clincal Rationale for Different Sequencing Strategies
- Impact of Various Interventional Modalities on Sequencing Rationale
- Tumor Heterogeneity and Combination Therapies
- Managing Adverse Event of Combination Therapies
- Discussion
|
| 5:45 - 6:45 p.m. |
Reception |
Friday, 6 June
Hosted at the Hyatt Centric-Chicago Magnificent Mile and in collaboration with the International Liver Cancer Association (ILCA) Single Topic Workshop
| Time |
Session |
| 7:00 a.m. |
Registration Open & Breakfast Served |
| 8:00 - 9:30 a.m. |
Session 5: Combination Therapies (IO + IO)
- EMERALD-1 and LEAP-012
- Will Combination Therapy Impact My Practice: Oncology Perspective
- Will Combination Therapy Impact My Practice: Hepatology Perspective
- Will Combination Therapy Impact My Practice: Surgical Perspective
- TARE: Ongoing Trials and IR Perspective of EMERALD-1 and LEAP-12
- Discussion
|
| 9:30 - 9:45 a.m. |
Break |
| 9:45 - 10:30 a.m. |
Session 6: TARE or...
- Solitary HCC: Ablative SBRT
- Solitary HCC: Radiation Segmentectomy
- BTC: HAI Pump
- BTC: TARE
- Multifocal Bilobar HCC: Systemic Therapy Alone
- Multifocal Bilobar HCC: TACE
- Multifocal Bilobar HCC: TARE
- Discussion
|
| 10:30 - 10:45 a.m. |
Break |
|
10:45 a.m. - 12:30 p.m.
|
Session 7: Practical y90
- Radiation Lobectomy
- Flow Diversion: What is it and Why?
- Extra-Hepatic Supply
- High Lung Shunts
- Lessons Learned from the European Perspective of TARE
- Lessons Learned from the Korean Perspective of TARE
- Vascular Invasion in the Era of Immunotherapy
- Discussion
|
| 12:30 - 1:30 p.m. |
Lunch |
| 1:30 - 2:50 p.m. |
Session 8: Multidisciplinary Case Review 1: Curative Intent
- HCC: Solitary HCC Beyond T2 with Elevated AFP
- HCC: Multi-focal within Downstaging Criteria
- BTC: Large Central Tumor
- HCC: Unilobar VP3 Invasion
|
| 2:50 - 3:00 p.m. |
Break |
| 3:00 - 4:20 p.m. |
Session 9:Multidisciplinary Case Review 2: Palliative Intent
- HCC: Infiltrative HCC with Elevated AFP
- HCC: Large Solitary Tumor
- HCC: Unilobar with Pulmonary Mets
- BTC: Recurrence Post-resection
|
| 4:30 |
Adjourn |